

## AMENDMENTS

### In the claims:

Please cancel claims 17 and 33.

Please amend the claims as follows:

1-14 (withdrawn)

**1** ~~15~~ (currently amended) An anti-PSCA monoclonal antibody that inhibits the growth of PSCA-expressing cancer cells in vivo, wherein the antibody internalizes upon binding to PSCA on the cancer cell, the antibody being produced by a hybridoma selected from the group of hybridomas having ATCC accession number PTA-717, PTA-718, PTA-719, PTA-720, PTA-880, or PTA-2265.

16-17 (canceled)

**3** ~~18~~ (currently amended) The antibody of claim ~~17~~<sup>2</sup> ~~19~~ which is produced in bacteria.

**2** ~~19~~ (currently amended) ~~The antibody of claim 15, which~~ An anti-PSCA monoclonal antibody that inhibits the growth of PSCA-expressing cancer cells in vivo, wherein the antibody internalizes upon binding to PSCA on the cancer cell, and wherein the antibody is a humanized form of an anti-PSCA antibody produced by a hybridoma selected from the group of hybridomas having ATCC accession number PTA-717, PTA-718, PTA-719, PTA-720, PTA-880, or PTA-2265.

**4** ~~20~~ (currently amended) The antibody of claim ~~15~~<sup>1</sup> or claim ~~19~~<sup>2</sup>, wherein the cancer cells are from a cancer selected from the group consisting of prostate cancer, bladder cancer and lung cancer.

**5** ~~21~~ (original) The antibody of claim 20, wherein the cancer is prostate cancer.

22-28 (withdrawn)

**6** ~~29~~ (currently amended) A composition comprising the antibody of claim ~~15~~<sup>1</sup> or claim ~~19~~, and a carrier.

**7** ~~30~~ (original) The composition of claim ~~29~~<sup>6</sup>, wherein the antibody is conjugated to a cytotoxic agent.

**8** ~~31~~ (original) The composition of claim ~~30~~<sup>7</sup>, wherein the cytotoxic agent is a maytansinoid.

<sup>6</sup>  
9 ~~32~~. (currently amended) The composition of claim ~~28~~, wherein the carrier is a pharmaceutical carrier.

33 (canceled)

34-57 (withdrawn)

---